References
- Isacson S, Nilsson I M. Defective fibrinolysis in blood and vein walls in recurrent ‘idiopathic’ venous thrombosis. Acta Chir Scand 1972; 138: 313–9
- Comp P C, Jacoks R M, Tayor F B, et al. The dilute whole blood clot lysis assay: A screeening method for identifying postoperative patients with a high incidence of deep venous thrombosis. J Lab Clin Med 1979; 93: 120–7
- Korninger C, Lechner K, Niessner H, Gossinger H, Kundi M. Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis. Thromb Haemostas 1984; 52: 127–30
- Nilsson I M. Phenformin and ethylestrenol in recurrent venous thrombosis. Progress in Chemical Fibrinolysis and Thrombosis, J F Davidson, M M Samama, P C Desnoyers. Raven Press, New York 1975; 1: 1–12
- Walker I D, Davidson J F. Long-term fibrinolytic enhancement with anabolic steroid therapy: A five-year study. Progress: Chemical Fibrinolysis and Thrombosis, J F Davidson, R M Rowan, M M Samama, P C Desnoyers. Raven Press, New York 1978; 3: 491–9
- Nilsson B, Nilsson I M, Hedner U. Delta 4-ethylestrenol in recurrent deep venous thrombosis. Acta Med Scand 1981; 209: 45–9
- Fearnley G R, Chakrabarti R. Increase of blood fibrinolytic activity by testosterone. Lancet 1962; II: 128–32
- Winther O. Testosterone and fibrinolytic activity. Scand J Clin Lab Invest 1967; 93: 207–10
- Warenhorst E, Risberg B. Effects of estrogen, orchidectomy, and cyproterone acetate on tissue fibrinolysis in patients with carcinoma of the prostate. Investigative Urology 1980; 18: 355–7
- Carlsson S, Astedt B. Oestrogenic treatment of prostatic cancer lowers the fibrinolytic activity in vein walls. Scand J Urol Nephrol 1974; 8: 169–72
- Louvet J P, Smilovici W, Bayard F. Dosage radioimmunologique de la testosterone plasmatique. Ann Biol Clin 1973; 31: 305–8
- Nisula B C, Dunn J F. Measurement of the testosterone binding parameters for both testosterone-estradiol binding globulin and albumin in individual serum samples. Steroids 1979; 34: 771–4
- Kluft C. Occurrence of Cl inactivator and other proteinase inhibitors in euglobulin fractions and their influence on fibrinolytic activity. Haemostasis 1976; 5: 136–46
- Sié P, Albarede J L, Robert A, et al. Tolerance and biological activity of pentosan polysulfate after intramuscular or subcutaneous administration for ten days in human volunteers. Thromb Haemostas 1986; 55: 86–9
- Nilsson I M, Ljungner H, Tengborn L. Two different mechanisms in patients with venous thrombosis and defective fibrinolysis: Low concentration of plasminogen activator or increased concentration of plasminogen activator inhibitor. Br Med J 1985; 290: 1453–6
- Wiman B, Ljungberg B, Chmielewska J, Urden G, Blomback M, Johnsson H. The role of the fibrinolytic system in deep vein thrombosis. J Lab Clin Med 1985; 105: 265–70
- Stalder M, Hauert J, Kruithof E KO, Bachmann F. Release of vascular plasminogen activator (v-PA) after venous stasis: Electrophoreticzymographic analysis of free and complexed v-PA. Br J Haematol 1985; 61: 169–76